Question
This study investigated the methodological rigour of randomised controlled trials (RCTs) of mental health apps for depression and anxiety, and whether quality has improved over time.
Study selection and analysisRCTs were drawn from the most recent meta-analysis of mental health...
Background
The prevalence of attention-deficit hyperactivity disorder (ADHD) drug treatment for youth and adults has been rising exponentially in Iceland over the past 15 years. The efficacy of ADHD drugs is not as strongly supported for adults as for children...
Background
Adolescence constitutes a critical window for preventing depression, but efforts have mostly targeted single risk factors. The Identifying Depression Early in Adolescence Risk Score (IDEA-RS) integrates easily obtainable sociodemographic variables and has been able to predict future depression across...
The page you are trying to reach is not available on our site. We are sorry for this inconvenience.
The page name may have changed, you may have happened upon a broken link, or the...
Background
The SARS-CoV-2 pandemic was a major stressful event that significantly affected healthcare providers.
ObjectiveTo evaluate the efficacy of a single-session intervention (SSI), with and without weekly personalised prerecorded videos, in preventing emotional distress worsening.
MethodsNationwide randomised clinical trial conducted in Brazil...
Background
Climate change affects people's mental health directly and indirectly. Climate anxiety, characterised by persistent worry and distress about environmental changes, is increasingly recognised as a factor affecting mental well-being. This study focused on potential implications of climate change worry...
Background
Social environment characteristics, including social relationships and cultural milieus, may influence the occurrence, course and management of depression. Effective questionnaires are needed to measure these factors and improve disease management.
ObjectiveWe aimed to (1) evaluate the social environment, such as...
Background
Metformin is a pharmacological candidate to mitigate second-generation antipsychotic (SGA)-induced weight gain in patients diagnosed with severe mental illnesses (SMI).
ObjectiveTo determine the incidence, prevalence and demographic patterns of metformin co-prescription among patients diagnosed with SMI initiating SGAs. To estimate...